Related Content Merck is paying $10.8 billion for a company with no approved drugs Johnson & Johnson is reportedly eyeing its second big heart device company acquisition Merck’s stock jumped 3% to about $130 during Thursday morning trading after the New Jersey-based pharmaceutical company reported …